{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T08:14:53Z","timestamp":1777450493276,"version":"3.51.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T00:00:00Z","timestamp":1762819200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-23323-1","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:28:13Z","timestamp":1762885693000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Inhibition of NLRP3 inflammasome activation alleviated liver injury and wasting effect in tumor-bearing mice"],"prefix":"10.1038","volume":"15","author":[{"given":"Shuaihui","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bo","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"key":"23323_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung, H. et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 71, 209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660 (2021).","journal-title":"CA Cancer J. Clin."},{"key":"23323_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/S1470-2045(19)30595-9","volume":"21","author":"MM Koo","year":"2020","unstructured":"Koo, M. M. et al. Presenting symptoms of cancer and stage at diagnosis: evidence from a cross-sectional, population-based study. Lancet Oncol. 21, 73\u201379. https:\/\/doi.org\/10.1016\/S1470-2045(19)30595-9 (2020).","journal-title":"Lancet Oncol."},{"key":"23323_CR3","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1038\/528182a","volume":"528","author":"C Lok","year":"2015","unstructured":"Lok, C. Cachexia: the last illness. Nature 528, 182\u2013183. https:\/\/doi.org\/10.1038\/528182a (2015).","journal-title":"Nature"},{"key":"23323_CR4","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon, K. et al. Definition and classification of cancer cachexia: an international consensus. Lancet Oncol. 12, 489\u2013495. https:\/\/doi.org\/10.1016\/S1470-2045(10)70218-7 (2011).","journal-title":"Lancet Oncol."},{"key":"23323_CR5","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1002\/jcsm.12528","volume":"11","author":"S Peixoto da Silva","year":"2020","unstructured":"Peixoto da Silva, S., Santos, J. M. O., Costa, E. S. M. P., Gil da Costa, R. M. & Medeiros, R. Cancer cachexia and its pathophysiology: links with sarcopenia, anorexia and asthenia. J. Cachexia Sarcopenia Muscle. 11, 619\u2013635. https:\/\/doi.org\/10.1002\/jcsm.12528 (2020).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"23323_CR6","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1007\/s10753-021-01429-8","volume":"44","author":"BJ Laird","year":"2021","unstructured":"Laird, B. J. et al. The emerging role of Interleukin 1beta (IL-1beta) in cancer cachexia. Inflammation 44, 1223\u20131228. https:\/\/doi.org\/10.1007\/s10753-021-01429-8 (2021).","journal-title":"Inflammation"},{"key":"23323_CR7","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","volume":"170","author":"HJ Patel","year":"2017","unstructured":"Patel, H. J. & Patel, B. M. TNF-alpha and cancer cachexia: molecular insights and clinical implications. Life Sci. 170, 56\u201363. https:\/\/doi.org\/10.1016\/j.lfs.2016.11.033 (2017).","journal-title":"Life Sci."},{"key":"23323_CR8","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20190450","author":"JE Rupert","year":"2021","unstructured":"Rupert, J. E. et al. Tumor-derived IL-6 and trans-signaling among tumor, fat, and muscle mediate pancreatic cancer cachexia. J. Exp. Med. 218. https:\/\/doi.org\/10.1084\/jem.20190450 (2021).","journal-title":"J. Exp. Med. 218"},{"key":"23323_CR9","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/s41591-020-0945-x","volume":"26","author":"R Suriben","year":"2020","unstructured":"Suriben, R. et al. Antibody-mediated Inhibition of GDF15-GFRAL activity reverses cancer cachexia in mice. Nat. Med. 26, 1264\u20131270. https:\/\/doi.org\/10.1038\/s41591-020-0945-x (2020).","journal-title":"Nat. Med."},{"key":"23323_CR10","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1172\/JCI118398","volume":"97","author":"T Tsujinaka","year":"1996","unstructured":"Tsujinaka, T. et al. Interleukin 6 receptor antibody inhibits muscle atrophy and modulates proteolytic systems in Interleukin 6 Transgenic mice. J. Clin. Invest. 97, 244\u2013249. https:\/\/doi.org\/10.1172\/JCI118398 (1996).","journal-title":"J. Clin. Invest."},{"key":"23323_CR11","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.1002\/jcsm.12346","volume":"9","author":"SC Kandarian","year":"2018","unstructured":"Kandarian, S. C. et al. Tumour-derived leukaemia inhibitory factor is a major driver of cancer cachexia and morbidity in C26 tumour-bearing mice. J. Cachexia Sarcopenia Muscle. 9, 1109\u20131120. https:\/\/doi.org\/10.1002\/jcsm.12346 (2018).","journal-title":"J. Cachexia Sarcopenia Muscle"},{"key":"23323_CR12","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature13528","volume":"513","author":"S Kir","year":"2014","unstructured":"Kir, S. et al. Tumour-derived PTH-related protein triggers adipose tissue Browning and cancer cachexia. Nature 513, 100\u2013104. https:\/\/doi.org\/10.1038\/nature13528 (2014).","journal-title":"Nature"},{"key":"23323_CR13","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.ando.2013.03.004","volume":"74","author":"JP Thissen","year":"2013","unstructured":"Thissen, J. P. & Loumaye, A. [Role of activin A and myostatin in cancer cachexia]. Ann. Endocrinol. (Paris). 74, 79\u201381. https:\/\/doi.org\/10.1016\/j.ando.2013.03.004 (2013).","journal-title":"Ann. Endocrinol. (Paris)"},{"key":"23323_CR14","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1002\/cncr.31128","volume":"124","author":"N Katakami","year":"2018","unstructured":"Katakami, N. et al. Anamorelin (ONO-7643) for the treatment of patients with non-small cell lung cancer and cachexia: results from a randomized, double-blind, placebo-controlled, multicenter study of Japanese patients (ONO-7643-04). Cancer 124, 606\u2013616. https:\/\/doi.org\/10.1002\/cncr.31128 (2018).","journal-title":"Cancer"},{"key":"23323_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.tibs.2022.10.002","author":"J Xu","year":"2022","unstructured":"Xu, J. & Nunez, G. The NLRP3 inflammasome: activation and regulation. Trends Biochem. Sci. https:\/\/doi.org\/10.1016\/j.tibs.2022.10.002 (2022).","journal-title":"Trends Biochem. Sci."},{"key":"23323_CR16","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/nrd.2018.97","volume":"17","author":"MSJ Mangan","year":"2018","unstructured":"Mangan, M. S. J. et al. Targeting the NLRP3 inflammasome in inflammatory diseases. Nat. Rev. Drug Discov. 17, 588\u2013606. https:\/\/doi.org\/10.1038\/nrd.2018.97 (2018).","journal-title":"Nat. Rev. Drug Discov"},{"key":"23323_CR17","doi-asserted-by":"publisher","first-page":"1049076","DOI":"10.3389\/fimmu.2022.1049076","volume":"13","author":"N Dubuisson","year":"2022","unstructured":"Dubuisson, N. et al. Inhibiting the inflammasome with MCC950 counteracts muscle pyroptosis and improves Duchenne muscular dystrophy. Front. Immunol. 13, 1049076. https:\/\/doi.org\/10.3389\/fimmu.2022.1049076 (2022).","journal-title":"Front. Immunol."},{"key":"23323_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10753-017-0667-5","volume":"41","author":"A Gugliandolo","year":"2018","unstructured":"Gugliandolo, A., Giacoppo, S., Bramanti, P. & Mazzon, E. NLRP3 inflammasome activation in a Transgenic amyotrophic lateral sclerosis model. Inflammation 41, 93\u2013103. https:\/\/doi.org\/10.1007\/s10753-017-0667-5 (2018).","journal-title":"Inflammation"},{"key":"23323_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s40635-016-0115-0","volume":"5","author":"N Huang","year":"2017","unstructured":"Huang, N. et al. Deletion of Nlrp3 protects from inflammation-induced skeletal muscle atrophy. Intensive Care Med. Exp. 5, 3. https:\/\/doi.org\/10.1186\/s40635-016-0115-0 (2017).","journal-title":"Intensive Care Med. Exp."},{"key":"23323_CR20","doi-asserted-by":"publisher","first-page":"E222","DOI":"10.1152\/ajpendo.00060.2017","volume":"313","author":"MJ McBride","year":"2017","unstructured":"McBride, M. J. et al. The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am. J. Physiol. Endocrinol. Metab. 313, E222\u2013E232. https:\/\/doi.org\/10.1152\/ajpendo.00060.2017 (2017).","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"23323_CR21","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1038\/s41420-021-00648-0","volume":"7","author":"L Wang","year":"2021","unstructured":"Wang, L. et al. Trimetazidine attenuates dexamethasone-induced muscle atrophy via inhibiting NLRP3\/GSDMD pathway-mediated pyroptosis. Cell. Death Discov. 7, 251. https:\/\/doi.org\/10.1038\/s41420-021-00648-0 (2021).","journal-title":"Cell. Death Discov"},{"key":"23323_CR22","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1139\/apnm-2019-0407","volume":"45","author":"ME Rosa-Caldwell","year":"2020","unstructured":"Rosa-Caldwell, M. E. et al. Hepatic alterations during the development and progression of cancer cachexia. Appl. Physiol. Nutr. Metab. 45, 500\u2013512. https:\/\/doi.org\/10.1139\/apnm-2019-0407 (2020).","journal-title":"Appl. Physiol. Nutr. Metab."},{"key":"23323_CR23","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/s41589-019-0277-7","volume":"15","author":"RC Coll","year":"2019","unstructured":"Coll, R. C. et al. MCC950 directly targets the NLRP3 ATP-hydrolysis motif for inflammasome Inhibition. Nat. Chem. Biol. 15, 556\u2013559. https:\/\/doi.org\/10.1038\/s41589-019-0277-7 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"23323_CR24","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1038\/nrm3904","volume":"15","author":"C Bonnans","year":"2014","unstructured":"Bonnans, C., Chou, J. & Werb, Z. Remodelling the extracellular matrix in development and disease. Nat. Rev. Mol. Cell. Biol. 15, 786\u2013801. https:\/\/doi.org\/10.1038\/nrm3904 (2014).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"23323_CR25","doi-asserted-by":"publisher","first-page":"729182","DOI":"10.3389\/fimmu.2021.729182","volume":"12","author":"JCR de Jesus","year":"2021","unstructured":"de Jesus, J. C. R. et al. Activation of the adipose tissue NLRP3 inflammasome pathway in cancer cachexia. Front. Immunol. 12, 729182. https:\/\/doi.org\/10.3389\/fimmu.2021.729182 (2021).","journal-title":"Front. Immunol."},{"key":"23323_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","volume":"15","author":"JM Argiles","year":"2018","unstructured":"Argiles, J. M., Stemmler, B., Lopez-Soriano, F. J. & Busquets, S. Inter-tissue communication in cancer cachexia. Nat. Rev. Endocrinol. 15, 9\u201320. https:\/\/doi.org\/10.1038\/s41574-018-0123-0 (2018).","journal-title":"Nat. Rev. Endocrinol."},{"key":"23323_CR27","doi-asserted-by":"publisher","first-page":"62","DOI":"10.15420\/cfr.2017:3:2","volume":"3","author":"M Sweeney","year":"2017","unstructured":"Sweeney, M., Yiu, A. & Lyon, A. R. Cardiac atrophy and heart failure in cancer. Card Fail. Rev. 3, 62\u201365. https:\/\/doi.org\/10.15420\/cfr.2017:3:2 (2017).","journal-title":"Card Fail. Rev."},{"key":"23323_CR28","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s12276-022-00752-w","volume":"54","author":"E Yeom","year":"2022","unstructured":"Yeom, E. & Yu, K. Understanding the molecular basis of anorexia and tissue wasting in cancer cachexia. Exp. Mol. Med. 54, 426\u2013432. https:\/\/doi.org\/10.1038\/s12276-022-00752-w (2022).","journal-title":"Exp. Mol. Med."},{"key":"23323_CR29","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1007\/s00726-011-0898-y","volume":"42","author":"R Silverio","year":"2012","unstructured":"Silverio, R., Laviano, A., Rossi Fanelli, F. & Seelaender, M. L-Carnitine induces recovery of liver lipid metabolism in cancer cachexia. Amino Acids. 42, 1783\u20131792. https:\/\/doi.org\/10.1007\/s00726-011-0898-y (2012).","journal-title":"Amino Acids"},{"key":"23323_CR30","doi-asserted-by":"publisher","first-page":"943","DOI":"10.1111\/acel.12126","volume":"12","author":"F Demontis","year":"2013","unstructured":"Demontis, F., Piccirillo, R., Goldberg, A. L. & Perrimon, N. The influence of skeletal muscle on systemic aging and lifespan. Aging Cell. 12, 943\u2013949. https:\/\/doi.org\/10.1111\/acel.12126 (2013).","journal-title":"Aging Cell."},{"key":"23323_CR31","doi-asserted-by":"publisher","first-page":"R1147","DOI":"10.1016\/j.cub.2017.09.019","volume":"27","author":"E Trefts","year":"2017","unstructured":"Trefts, E., Gannon, M. & Wasserman, D. H. The liver. Curr. Biol. 27, R1147\u2013R1151. https:\/\/doi.org\/10.1016\/j.cub.2017.09.019 (2017).","journal-title":"Curr. Biol."},{"key":"23323_CR32","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1038\/s41590-021-00886-5","volume":"22","author":"BR Sharma","year":"2021","unstructured":"Sharma, B. R. & Kanneganti, T. D. NLRP3 inflammasome in cancer and metabolic diseases. Nat. Immunol. 22, 550\u2013559. https:\/\/doi.org\/10.1038\/s41590-021-00886-5 (2021).","journal-title":"Nat. Immunol."},{"key":"23323_CR33","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.1016\/j.jhep.2017.01.022","volume":"66","author":"AR Mridha","year":"2017","unstructured":"Mridha, A. R. et al. NLRP3 inflammasome Blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J. Hepatol. 66, 1037\u20131046. https:\/\/doi.org\/10.1016\/j.jhep.2017.01.022 (2017).","journal-title":"J. Hepatol."},{"key":"23323_CR34","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1038\/s41589-019-0278-6","volume":"15","author":"A Tapia-Abellan","year":"2019","unstructured":"Tapia-Abellan, A. et al. MCC950 closes the active conformation of NLRP3 to an inactive state. Nat. Chem. Biol. 15, 560\u2013564. https:\/\/doi.org\/10.1038\/s41589-019-0278-6 (2019).","journal-title":"Nat. Chem. Biol."},{"key":"23323_CR35","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/cmi.2011.53","volume":"9","author":"R Xu","year":"2012","unstructured":"Xu, R., Zhang, Z. & Wang, F. S. Liver fibrosis: mechanisms of immune-mediated liver injury. Cell. Mol. Immunol. 9, 296\u2013301. https:\/\/doi.org\/10.1038\/cmi.2011.53 (2012).","journal-title":"Cell. Mol. Immunol."},{"key":"23323_CR36","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41575-020-00372-7","volume":"18","author":"T Kisseleva","year":"2021","unstructured":"Kisseleva, T. & Brenner, D. Molecular and cellular mechanisms of liver fibrosis and its regression. Nat. Rev. Gastroenterol. Hepatol. 18, 151\u2013166. https:\/\/doi.org\/10.1038\/s41575-020-00372-7 (2021).","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"23323_CR37","doi-asserted-by":"publisher","first-page":"105971","DOI":"10.1016\/j.bioorg.2022.105971","volume":"127","author":"WX Niu","year":"2022","unstructured":"Niu, W. X. et al. Dehydromevalonolactone ameliorates liver fibrosis and inflammation by repressing activation of NLRP3 inflammasome. Bioorg. Chem. 127, 105971. https:\/\/doi.org\/10.1016\/j.bioorg.2022.105971 (2022).","journal-title":"Bioorg. Chem."},{"key":"23323_CR38","doi-asserted-by":"publisher","unstructured":"Meier, R. P. H. et al. Interleukin-1 receptor antagonist modulates liver inflammation and fibrosis in mice in a Model-Dependent manner. Int. J. Mol. Sci. 20 https:\/\/doi.org\/10.3390\/ijms20061295 (2019).","DOI":"10.3390\/ijms20061295"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23323-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23323-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T18:28:14Z","timestamp":1762885694000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-23323-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["23323"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-23323-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,11]]},"assertion":[{"value":"11 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Our research was approved by the Ethics Committee of Zhongnan Hospital of Wuhan University (IACUC approval number - WP20240045). This study is reported in accordance with ARRIVE guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}],"article-number":"39533"}}